Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.
Temesgen
Zelalem
Z
Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu
Feinberg
Judith E
JE
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D015683:Gene Products, gag / Q000037:antagonists & inhibitors*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D013386:Succinates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D014315:Triterpenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D053978:Pentacyclic Triterpenes
D015683:Gene Products, gag; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes